SynVaccine

SynVaccine Overview

SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology. The company utilizes a multidisciplinary approach combining technologies, such as synthetic biology, virology, bio-informatics, engineering, and robotics, to make viruses that can be used to develop new vaccines. SynVaccine's technology enables the design and fabrication of viral genomes using a safety-focused design approach. The resulting viruses have the potential to overcome the limitations of those found in nature or developed through traditional technologies. SynVaccine was founded as part of Rad BioMed, an Israel-based evergreen family fund that invests in early-stage biomedical start-ups, and on the basis of commercialized research from Tel Aviv University and Weizmann Institute of Science led by Professor Tamir Tuller.

Cumulative Funding Raised Over Time ($)

Latest News

Nov 6, 2017 · www.globes.co.il

growth-positive

Israeli viral vaccines co SynVaccine raises $1.7m

Israeli startup SynVaccine, which develops vaccines based on synthetic biology, has raised $1.7 million. The company has developed a proprietary technology that identifies significant parts of viruses and develops vaccines for them. SynVaccine sees its future in building positive viruses that strengthen the immune systems activity. The companys list of investors includes Yehuda and Prof. Nava Zisapel, Sapir Venture Partners, and Pix Vine Capital.

Investment

Funding

Team Members

4

Employees: 1-10

Web & Social Links

Locations

HaBarzel Street 27, Tel Aviv-Yafo, Israel

Photos & Videos

1 item(s)

SynVaccine Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info